Welcome to Advances in
Advances in Multiple Sclerosis (MSAdvances) has been designed to bring you, the consumer, up to date information on the management and treatment of Multiple Sclerosis (MS) through the use of intravenous immune globulin (IVIG). IVIG has been demonstrated in multiple clinical trials reported in the medical literature to have an impact on two important considerations in relapsing-remitting Multiple Sclerosis. Firstly IVIG reduces the frequency of the acute exacerbation and secondly it reduces the intensity and duration of the acute exacerbation.
This site explores the medical literature describing these benefits associated with IVIG. Along with articles of interest, expert interviews and links to other useful sites, MSAdvances will be hosting a chat room where you can interact directly with clinical experts in the field of MS. Watch our site in the coming weeks for information about the date and time for the chat room. We welcome your questions and feedback.